Intravitreal bevacizumab plus propranolol for neovascular age-related macular degeneration (the BEVALOL study): a phase I clinical trial.
José Edísio da Silva Tavares NetoFrancyne Veiga Reis CyrinoMoises Moura LucenaIngrid U ScottAndré Márcio Vieira MessiasRodrigo JorgePublished in: International journal of retina and vitreous (2023)
In this 12 week trial of a combination of intravitreal bevacizumab and propranolol for treatment of nARMD, no adverse events or signals of ocular toxicity were observed. Further studies using this combination therapy are warranted. Trial Registration Project registered in Plataforma Brasil with CAAE number 28108920.0.0000.5440 and approved in ethics committee of Clinics Hospital of Ribeirao Preto Medicine School of São Paulo University-Ribeirão Preto, São Paulo, Brazil (appreciation number 3.999.989 gave the approval).
Keyphrases
- age related macular degeneration
- combination therapy
- clinical trial
- phase iii
- phase ii
- study protocol
- open label
- primary care
- metastatic colorectal cancer
- randomized controlled trial
- public health
- physical activity
- oxidative stress
- quality improvement
- mental health
- vascular endothelial growth factor
- double blind
- case control
- big data
- adverse drug
- acute care
- diabetic retinopathy
- deep learning